ClinicalTrials.gg
RecruitingNCT06639061Updated Nov 1, 2024

Neuromodulation of the Hippocampus to Reduce Intrusive Re-Experiencing in PTSD: A Randomized Controlled Trial

A Phase 2 interventional study of Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS) and Sham stimulation using repetitive transcranial magnetic stimulation (rTMS) in PTSD - Post Traumatic Stress Disorder and Intrusive Memories of Traumatic Event(s), sponsored by Tel Aviv University. Recruiting at 1 site in Israel. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Tel Aviv University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if non-invasive neurostimulation of memory-related brain areas works to treat intrusive memory symptoms in adults patients with posttraumatic stress disorder (PTSD). It will also learn about the effect of this neuromodulation procedure on reorganization of memory-related brain networks. The main questions it aims to answer are:

Does neuromodulation lower the number of times and the emotional severity participants intrusive memories? Does neuromodulation reduces the overall severity of PTSD? Researchers will compare neuromodulation targeting the hippocampus (a memory-related brain structure) to a control stimulation in an area not related to memory processes to see if hippocampus neuromodulation works to treat intrusive trauma memories and PTSD.

Participants will:

  1. Undergo magnetic resonance imaging (MRI) scans before and after neuromodulation to: a) determine a personalized neuromodulation target; and b) to measure changes in brain function from before to after treatment.
  2. Receive hippocampus neuromodulation or a control neuromodulation once a week for 5 weeks.

Keep a daily diary of their symptoms and the number of times they experience intrusive trauma memories.

Read the detailed description

Intrusive trauma memories are a hallmark of posttraumatic stress disorder (PTSD), and the least treatment responsive. Thus, revealing neurocognitive mechanisms associated with intrusive trauma memories has been indexed a priority. Prior work shows that targeting hippocampal circuitry modulates functional connectivity among distributed cortical-hippocampal network regions and alters memory performance in healthy participants. In the current clinical trial we test hypotheses on the clinical effects of such stimulation in a two-arms randomized controlled trial: Trauma memory reactivation + targeted hippocampal transcranial magnetic stimulation TMS (R-H-TMS) and Trauma memory reactivation + Control TMS (over the SMA; R-C-TMS). We will test a) Hippocampus seed-based connectivity patterns - revealing the impact of the targeted stimulation on extended memory brain networks; and b) frequency and severity of intrusive memory symptoms. The R-H-TMS vs. R-C-TMS contrast will speak to specificity of the noted effects to hippocampal stimulation.

02

Conditions studied

  • PTSD - Post Traumatic Stress Disorder
  • Intrusive Memories of Traumatic Event(s)

Keywords

  • PTSD
  • TMS
  • MRI
03

In context

Combat Disorders

204 studies on the registry are indexed under Combat Disorders; 93 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 171 interventional studies indexed under Combat Disorders.

Browse Combat Disorders studies →

Lead sponsor

Tel Aviv University is the lead sponsor of 101 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Aged of 20-65 years.
  • Meet a diagnosis of PTSD according to as tested by a structured clinical interview (Clinician-Administered PTSD Scale for DSM-5 - CAPS-5).
  • CAPS-5 total score greater or equal to 33.
  • Endorsement of intrusive symptoms (flashbacks, nightmares, or intrusive memories) with a frequency of at least 3 times a week.
  • Meeting the accepted criteria for inclusion in an MRI examination.

Exclusion Criteria:

  • Meeting a diagnosis of Complex PTSD or personality disorder.
  • Psychotic disorder, bipolar disorder, or a developmental neuropsychological disorder (autism, mental retardation).
  • Use of psychiatric medications (except for the medications listed in section 4.a of the study protocol if the medication dosage is stable in the last three months and does not change during the study.
  • Exclusion rules in TMS research (see guidelines).
  • Use of the following drugs: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma- hydroxybutyrate (GHB), alcohol, theophylline
  • Epilepsy or use of anti-epileptic drugs.
  • Traumatic head injuries or head surgery.
  • Implanted metallic body (except fillings/amalgam bites/orthodontic fixations approved for MRI), electrodes or a pacemaker.
  • Migraines
  • Pregnant women
  • Hearing problems
  • Drinking alcohol 24 hours before the TMS session
  • Repeated episodes of fainting with loss of consciousness and/or an event of fainting with loss of consciousness in the past year.
  • The accepted exclusion criteria for an MRI examination
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Trauma memory reactivation + targeted hippocampal TMS

    Brain stimulation using repetitive transcranial magnetic stimulation (rTMS) will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, once a week over 5 weeks. The scalp stimulation area will be determined based on a resting state fMRI scan identifying a cortical area that is most strongly functionally connected to the left hippocampal target of each patient.

    Device: Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)

  • Sham comparator
    Trauma memory reactivation + targeted sham TMS

    Brain stimulation using repetitive transcranial magnetic stimulation (rTMS) will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, once a week over 5 weeks. The scalp stimulation area will be determined based on a resting state fMRI scan identifying a cortical area that has near zero functional connectivity with the left hippocampal target of each patient.

    Device: Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)

Interventions

  • DeviceHippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)

    We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.

    Also known as: TMS, MRI

  • DeviceSham stimulation using repetitive transcranial magnetic stimulation (rTMS)

    We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.

    Also known as: TMS, MRI

06

What researchers measure

Primary outcomes

  1. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total score

    The CAPS-5 is a 30-item structured interview that can be used to make current (past month or week) diagnosis of PTSD \& make lifetime diagnosis of PTSD.

    Time frame: Baseline, 6 weeks, 3-months

Secondary outcomes

  1. PTSD Checklist for DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-reported measured based on the DSM-5 PTSD symptoms and assessing PTSD symptoms endorsement and severity.

    Time frame: Baseline, 6 weeks, 3-months

  2. Intrusive trauma memories diary

    The amount, frequency and emotional effect of intrusive traumatic memories, measured by a daily self-report digital diary.

    Time frame: Through study completion, an average of 8 weeks

  3. Patient Health Questionnaire - 9 (PHQ-9)

    Measures severity of depression symptoms as listed in the DSM-5

    Time frame: Baseline, 6 weeks, 3-months

Other outcomes

  1. credibility/expectancy questionnaire (CEQ)

    Measures treatment expectancies and credibility

    Time frame: Baseline

  2. fMRI Neuroimaging

    Functional connectivity, indicating the level of synchronous activity of certain brain regions during rest (temporal correlation is usually expressed as a Pearson's r). Derived from the fMRI scans, and compared between the two groups as a function of time.

    Time frame: Baseline, 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data from the study will be shared in accordance with local laws related to patient data sharing.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Uploaded by October 2026 (before data analyses starts), will stay on.

Access criteria: Deidentified clinical outcome data will be deposited in an open access repository in compliance with local patient information sharing laws. Reference to the repository will be embedded in the published report for unrestricted access. De-identified MRI data matrices will be shared upon request and in compliance with local patient information sharing laws.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Nov 2028
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639061
Responsible party
Yair Bar-Haim (Professor, Tel Aviv University) — Principal investigator
First posted
Oct 15, 2024
Start date
Nov 1, 2024
Primary completion
Oct 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 1, 2024

Study contacts

Yair Bar-Haim, PhD
Contact
yair1@tauex.tau.ac.il
972-3-6405465
Nitzan Censor, PhD
Contact
censornitzan@tauex.tau.ac.il
972-3-6406105
Yair Bar-Haim, PhD
principal investigator · Tel Aviv University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion